54
6
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2340 |
AC1NS4RE
|
Tyrosinase | Proteases/Proteasome |
是一种化学合成中的砌块 | |||
T1938 |
FLT3-IN-2
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
FLT3-IN-2 是 FLT3 抑制剂(IC50<1 μM)。 | |||
T15335 |
FN-1501
|
FLT; CDK | Angiogenesis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
FN-1501 是一种有效的 FLT3 和 CDK 抑制剂,具有抗肿瘤的活性,对 CDK2/cyclin A、CDK4/cyclin D1、CDK6/cyclin D1 和 FLT3 的 IC50值分别为 2.47、0.85、1.96 和 0.28 nM。 | |||
T6138 |
TCS 359
FLT3 Inhibitor |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
TCS 359 (FLT3 Inhibitor) 是 2-酰基氨基噻吩-3-甲酰胺,是选择性FLT3抑制剂(IC50:42 nM),能够抑制 MV4-11 细胞增殖(IC50:340 nM)。 | |||
T4428 |
CCT241736
|
FLT; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
CCT241736 是一种口服生物可利用的双重 FLT3/Aurora 激酶抑制剂,还抑制临床相关的 FLT3 耐药突变体,包括 FLT3-ITD 和 FLT3。它是 CCT137690 的高级类似物,是治疗人类恶性肿瘤的临床前开发候选物。 | |||
T11298 |
FLT3-IN-3
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
FLT3-IN-3 是 FLT3抑制剂,能够抑制 FLT3 WT (IC50:13 nM) 和 FLT3 D835Y (IC50:8 nM) 。 | |||
T6756 |
AMG 925
|
FLT; CDK | Angiogenesis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
AMG 925 是一种选择性FLT3/CDK4双重抑制剂,IC50分别为 1 nM 和 3 nM。 | |||
T2272 |
BPR1J-097
BPR1J097 |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
BPR1-J097 是新型的、强效的FLT3抑制剂 (IC50:11 nM)。 | |||
T3065 |
TG101209
|
Apoptosis; FLT; c-RET; JAK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
TG101209 是一种选择性有效的 JAK2抑制剂,IC50值为 6 nM。它能抑制 Flt3和RET 的活性,IC50值分别为 25 nM 和 17 nM。 | |||
T6020 |
Pacritinib
SB1518 |
FLT; Tyrosine Kinases; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Pacritinib (SB1518) 是一种野生型 JAK2和 JAK2V617F 突变型抑制剂,IC50分别为 23 和 19 nM。它也抑制 FLT3及其突变型 FLT3D835Y,IC50分别为 22 和 6 nM。 | |||
T6115 |
Fostamatinib
R788,福他替尼 |
FLT; Syk; Monoamine Transporter; Adenosine Receptor | Angiogenesis; GPCR/G Protein; Membrane transporter/Ion channel; Neuroscience; Tyrosine Kinase/Adaptors |
Fostamatinib (R788) 是一种口服具有活力的 R406 前药。其中R406 是具有口服活性的,有效的,ATP 竞争性的Syk/FLT3抑制剂(Ki:30 nM,IC50:41 nM),也能够抑制 Lyn (IC50:63 nM) 和 Lck (IC50:37 nM)。 | |||
T2640 |
Rebastinib
DCC2036,DCC 2036,DCC-2036 |
Apoptosis; FLT; Bcr-Abl; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Rebastinib (DCC-2036) 是一种口服有效的,非 ATP 竞争性的 Bcr-Abl 抑制剂,作用于 Abl1WT 和 Abl1T315I,IC50分别为 0.8 nM 和 4 nM,还抑制 LYN、SRC、HCK、FGR、FLT3、KDR 和 Tie-2,对 c-Kit 的活性低。Rebastinib 对 Angiopoietin2-Tie2通路具有抑制作用。 | |||
T7673 |
ATH686
ATH 686 |
Apoptosis; FLT | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
ATH686 是一种选择性的,ATP 竞争性的FLT3抑制剂,具有抗白血病作用。它靶向突变 FLT3 蛋白激酶活性,并通过诱导凋亡和抑制细胞周期来抑制具有 FLT3 突变的细胞的增殖。 | |||
T4409 |
Gilteritinib
吉列替尼,ASP2215 |
FLT; TAM Receptor; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Gilteritinib (ASP2215) 是一种 FLT3 抑制剂 (IC50:0.29 nM),也是一种 AXL 抑制剂 (IC50:0.73 nM),具有 ATP 竞争性。 | |||
T6350 |
CHIR-124
CHIR124,CHIR 124 |
Apoptosis; GSK-3; FLT; Chk; PDGFR; Src | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; PI3K/Akt/mTOR signaling; Stem Cells; Tyrosine Kinase/Adaptors |
CHIR-124 是一种选择性 Chk1抑制剂,IC50值为 0.3 nM,可有效抑制 PDGFR 和 FLT3,IC50值分别为 6.6 nM 和 5.8 nM。 | |||
T9473 |
4SC-203
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
4SC-203 是一种具有潜在的抗肿瘤活性的多激酶抑制剂。它对 FLT3/STK1、 FLT3 的突变形式以及 VEGFRs 具有选择性抑制作用。 | |||
TQ0235 |
AC710
|
FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AC710是一种 PDGFR 抑制剂,能够作用于 FLT3 (Kd:0.6),CSF1R (Kd:1.57),KIT (Kd:1),PDGFRα (Kd:1.3) 和 PDGFRβ (Kd:1.0)。 | |||
T8317 |
5'-Fluoroindirubinoxime
5'-FIO |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
5'-Fluoroindirubinoxime (5'-FIO) 是一种 Indirubin 的衍生物,是一种 FLT3 的抑制剂(IC50:15 nM)。 | |||
T16144 |
MRX-2843
UNC2371 |
Others; FLT | Angiogenesis; Others; Tyrosine Kinase/Adaptors |
MRX-2843 (UNC2371) 是ATP 竞争性的、具有口服活性的MERTK 和FLT3酪氨酸激酶抑制剂 (TKI),它们的IC50分别为 1.3 nM 和 0.64 nM。 | |||
T3455 |
Merestinib
LY2801653 |
Discoidin Domain Receptor (DDR); FLT; c-Met/HGFR; ROS; ROS Kinase | Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors |
Merestinib (LY2801653) 是一种有效的口服生物可利用的具有抗肿瘤活性的c-Met 抑制剂。 | |||
T2341 |
KW-2449
KW2449 |
Apoptosis; FGFR; FLT; JAK; Bcr-Abl; Src; c-Kit; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
KW-2449是一种多靶点激酶抑制剂,对FLT3,ABL,ABLT315I 和极光激酶的IC50值分别为6.6,14,4 和 48 nM。 | |||
T3068 |
AT9283
J-504568 |
Apoptosis; FLT; JAK; Bcr-Abl; Aurora Kinase; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
AT9283 (J-504568) 是一种多靶点激酶抑制剂,抑制多种实体瘤在体内外的生长和存活,有效抑制Aurora A/B,JAK2/3,Abl (T315I),和Flt3,IC50值范围为 1-30 nM。 | |||
T38562 |
AKN-028
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
AKN-028 是酪氨酸激酶 FLT3的抑制剂,可剂量依赖性的诱导 FLT3的自磷酸化。 | |||
T7007 |
UNC2025
mrx-6313,UNC-2025,UNC 2025 |
FLT; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
UNC2025 (mrx-6313) 是高效的、具有口服活性的、ATP 竞争性的Mer/Flt3双抑制剂,IC50值分别为 0.74 nM 和 0.8 nM。它对MERTK 的选择性比 Axl 高 45 倍(IC50:122 nM;Ki:13.3 nM)。它具有良好的 PK 特性,可用于研究急性白血病。 | |||
T9027 |
CA-4948
Emavusertib |
IRAK; FLT | Angiogenesis; Immunology/Inflammation; NF-κB; Tyrosine Kinase/Adaptors |
CA-4948 (Emavusertib) 是一种IRAK4抑制剂,也是一种FLT3抑制剂,具有抗肿瘤作用。 | |||
T2620 |
G-749
G749 |
Apoptosis; FLT; c-RET; TAM Receptor; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
G-749 是一种新型 FLT3 抑制剂,对 FLT3 野生型和突变体有持续的抑制作用,IC50值分别为 0.4 nM 和 0.6 nM。它可用于急性髓系白血病的耐药研究。 | |||
T6174 |
R406
R-406 besylate |
Apoptosis; FLT; Syk | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
R406 (R-406 besylate) 是一种具有口服活性的 ATP 竞争性 Syk/FLT3抑制剂,Ki 为 30 nM。它有效抑制 Syk 激酶活性,IC50为 41 nM。它还抑制 Lyn 和 Lck,IC50值分别为 63 nM 和 37 nM。它可减轻免疫复合物介导的炎症。 | |||
T0093L |
Sorafenib
索拉非尼,Bay 43-9006 |
Apoptosis; Raf; VEGFR; FLT; Ferroptosis; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Sorafenib (Bay 43-9006) 是一种多激酶抑制剂,抑制 Raf-1、B-Raf、VEGFR2、VEGFR3、VEGFR4、PDGFRβ、FLT3、c-Kit 等 (IC50=6/22/90/15/20/20/57/58 nM),具有口服活性。Sorafenib 具有抗肿瘤活性,可以诱导细胞自噬和凋亡,也可以激动铁死亡。 | |||
T1836 |
AZD2932
|
VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。 | |||
T2638 |
Gandotinib
LY2784544 |
VEGFR; FGFR; FLT; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Gandotinib (LY2784544) 是一种JAK2抑制剂,IC50为 3 nM。它也抑制FLT3、FLT4、FGFR2、TYK2 和 TRKB,IC50分别为 4、25、32、44 和 95 nM。 | |||
T4209 |
TAK-659 hydrochloride
TAK-659 |
VEGFR; FLT; Tyrosine Kinases; JAK; Syk | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
TAK-659 hydrochloride (TAK-659) 是可逆的、高效的、选择性的、口服有效的 SYK/FLT3 双抑制剂,对 SYK 和 FLT3 作用的IC50值分别为 3.2 nM、4.6 nM。它能诱导肿瘤细胞死亡,却不作用于非肿瘤细胞,对慢性淋巴细胞白血病具有潜在的研究价值。 | |||
T2467 |
R406 free base
R406 (free base) |
Apoptosis; FLT; Syk | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
R406 free base (R406(free base)) 是一种具有口服活性的,ATP 竞争性的Syk/FLT3抑制剂,Ki 为 30 nM。它有效抑制 Syk 激酶活性,IC50为 41 nM,可减轻免疫复合物介导的炎症。它还抑制 Lyn 和 Lck,IC50分别为 63 nM 和 37 nM。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
T2051 |
SKLB4771
FLT3-IN-1,FLT3-IN-1 |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
SKLB4771 (FLT3-IN-1) 是一种新型的、高效的 Flt3 抑制剂 (IC50:10nM)。 | |||
T2677 |
Crenolanib
ARO 002,CP-868596 |
FLT; PDGFR; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Crenolanib (ARO 002) 是一种口服生物可利用的 III 型酪氨酸激酶抑制剂,抑制 FLT3和 PDGFRα/β的 IC50分别为 4、11和 3.2 nM。 | |||
T41003 |
KG5
|
Raf; FLT; PDGFR; c-Kit | Angiogenesis; MAPK; Tyrosine Kinase/Adaptors |
KG5 是 PDGFRβ 和 B-Raf 的双重变构抑制剂,对 PDGFRβ 和 PDGFRα 的 Kd 分别为 520 nM 和 300 nM。 KG5 抑制 FLT3、KIT 和 c-Raf,具有抗癌和抗血管生成活性。 | |||
T2358 |
ENMD-2076
|
Apoptosis; VEGFR; FGFR; FLT; c-RET; PDGFR; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
ENMD2076是一种多靶点激酶抑制剂,抑制Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1、FGFR2、Src、PDGFRα的IC50值分别为1.86、14、58.2、15.9、92.7、70.8、20.2 and 56.4 nM。 | |||
T0093 |
Sorafenib tosylate
甲苯磺酸索拉非尼,Bay 43-9006 |
Apoptosis; Raf; VEGFR; FLT; Ferroptosis; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Sorafenib tosylate (Bay 43-9006) 是一种口服活性Raf 抑制剂,也是铁死亡激动剂。它是多激酶抑制剂,对VEGFR2,VEGFR3,PDGFRβ,FLT3和c-Kit 的IC50分别为 90 nM,15 nM,20 nM,57 nM 和 58 nM。它诱导细胞自噬和凋亡,有抗肿瘤活性。 | |||
T8482 |
Ripretinib
DCC-2618,瑞普替尼 |
Apoptosis; VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Ripretinib (DCC-2618) 是一种口服生物利用的,选择性 KIT 和 PDGFRA 开关控制抑制剂,具有抗肿瘤作用并诱导细胞凋亡。它专门针对 KIT 和 PDGFRA 的野生型和突变型并与之结合在其开关口袋结合位点,从而防止这些激酶从无活性构象转变为有活性构象,并使它们的野生型和突变体形式失活。 | |||
T4053 |
AST 487
NVP-AST 487 |
VEGFR; FLT; c-RET; Bcr-Abl; c-Kit | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
AST 487 (NVP-AST 487) 是 RET 激酶抑制剂 (IC50:880 nM),能够抑制 RET 自磷酸化,及下游效应器激活,也抑制 Flt-3 (IC50:520 nM)。 | |||
T2066 |
Quizartinib
AC220,奎扎替尼 |
Apoptosis; FLT; Autophagy; Ligands for Target Protein for PROTAC | Angiogenesis; Apoptosis; Autophagy; PROTAC; Tyrosine Kinase/Adaptors |
Quizartinib (AC220) 是一种具有口服活性的高选择性Ⅱ 型 FLT3酪氨酸激酶抑制剂,可诱导细胞凋亡。它抑制 Wt FLT3 和 突变型 FLT3-ITD 自磷酸化,IC50分别为 4.1 nM 和 1.1 nM。它可通过优化的 linker 与 VHL 配体连接,从而形成 PROTAC Flt3 降解剂。 | |||
T2516 |
Amuvatinib
MP470,HPK 56 |
Apoptosis; FLT; c-Met/HGFR; c-RET; DNA/RNA Synthesis; PDGFR; c-Kit | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Tyrosine Kinase/Adaptors |
Amuvatinib (MP470) 是一种多靶点酪氨酸激酶抑制剂,对突变 c-Kit,PDGFRα,Flt3,c-Met 和 c-Ret 具有活性。它还是一种 DNA 修复抑制剂,靶向蛋白 DNA 修复 RAD51,从而破坏 DNA 损伤修复,具有抗肿瘤活性。 | |||
T2605 |
Fostamatinib Disodium
Tamatinib Fosdium,福他替尼二钠盐,R788(Disodium),R788 Disodium,R788 (Fostamatinib) Disodium |
FLT; Syk | Angiogenesis; Tyrosine Kinase/Adaptors |
Fostamatinib Disodium (R788 Disodium) 是一种口服具有活力的 R406 前药。其中R406 是具有口服活性的,有效的,ATP 竞争性的Syk/FLT3抑制剂(Ki:30 nM,IC50:41 nM),也能够抑制 Lyn (IC50:63 nM) 和 Lck (IC50:37 nM)。 | |||
T1667 |
Tandutinib
MLN518,CT53518,NSC726292,坦度替尼 |
Apoptosis; FLT; CSF-1R; PDGFR; Src; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Tandutinib (CT53518) 是一种选择性 FLT3抑制剂,其 IC50为 0.22 μM。它还抑制c-Kit 和PDGFR,其IC50分别为 0.17 μM 和 0.20 μM。它可穿透血脑屏障,用于急性骨髓性白血病。 | |||
T6711 |
Tyrphostin AG1296
Tyrphostin AG 1296,AG 1296 |
Apoptosis; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Tyrphostin AG1296 (Tyrphostin AG 1296) 抑制人PDGF α和β受体以及相关干细胞因子受体的信号传导,是一种选择性血小板衍生生长因子受体抑制剂,IC50值为 0.8 μM。 | |||
T21503 |
(E/Z)-Zotiraciclib
(E/Z)-TG02,(E/Z)-SB1317 |
FLT; JAK; CDK | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
(E/Z)-Zotiraciclib ((E/Z)-TG02) 是一种 CDK2、JAK2和FLT3的抑制剂,IC50分别为 13、73 和 56 nM。 | |||
T2586 |
Cabozantinib
卡博替尼,XL184,BMS-907351 |
Apoptosis; VEGFR; FLT; c-Met/HGFR; c-RET; TAM Receptor; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Cabozantinib (XL184) 是一种多靶点酪氨酸激酶受体抑制剂,可以抑制 VEGFR2、c-Met、Kit、Axl 和 Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM)。Cabozantinib 具有抗肿瘤和抗血管生成活性。 | |||
T7104 |
Dovitinib lactate
CHIR-258 lactate,多韦替尼乳酸盐,TKI-258 lactate |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib lactate (TKI-258 lactate) 是一种多靶点的酪氨酸激酶抑制剂,抑制FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和PDGFRα/β的IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T6289 |
Dovitinib
TKI258,多韦替尼,CHIR-258,度维替尼 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib (CHIR-258) 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂,具有抗肿瘤作用。 | |||
T4349 |
Sitravatinib
MG516,MGCD516 |
Discoidin Domain Receptor (DDR); VEGFR; FLT; Trk receptor; TAM Receptor; c-Kit; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Sitravatinib (MGCD516) 是一种有口服活性的受体酪氨酸激酶抑制剂。它单独使用即具有有效的抗肿瘤功效,且通过促进抗肿瘤免疫微环境增强了 PD-1 阻断的活性。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01247 |
FLT3 Protein, Human, Recombinant (T227M, His)
FLK2,FLK-2,CD135,STK1,fms-related tyrosine... |
Human | HEK293 |
The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD prot... | |||
TMPK-00523 |
FLT3 Protein, Cynomolgus, Recombinant (hFc)
FLT-3,FLK2,STK-1,CD135 |
Cynomolgus | HEK293 |
The Flt-3 (fms-like tyrosine kinase) receptor, also named Flk-2 (fetal liver kinase) and Stk-1(stem cell tyrosine kinase) is a member of the class III subfamily of receptor tyrosine kinases that also includes KIT, the receptor for SCF and FMS, the receptor for M-CSF. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 ... | |||
TMPK-00416 |
FLT3 Protein, Human, Recombinant (His & Avi), Biotinylated
STK-1,FLK2,CD135,FLT-3 |
Human | CHO |
The Flt-3 (fms-like tyrosine kinase) receptor, also named Flk-2 (fetal liver kinase) and Stk-1(stem cell tyrosine kinase) is a member of the class III subfamily of receptor tyrosine kinases that also includes KIT, the receptor for SCF and FMS, the receptor for M-CSF. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 ... | |||
TMPY-05738 |
FLT3 Protein, Human, Recombinant (hFc)
FLK2,CD135,fms-related tyrosine kinase 3,F... |
Human | HEK293 |
The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD prot... | |||
TMPY-06938 |
FLT3 Protein, Human, Recombinant (hFc & Avi), Biotinylated
fms-related tyrosine kinase 3,CD135,STK1,F... |
Human | HEK293 |
The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD prot... | |||
TMPY-03704 |
FLT3 Protein, Mouse, Recombinant (His)
wmfl,Flk-2,Flk2,Flt-3,CD135,B230315G04,fms... |
Mouse | HEK293 |
The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD prot... |